Overview

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

Status:
RECRUITING

Trial end date:
2027-02-01

Target enrollment:

Participant gender:

Summary

This is a Phase I/II Study to determine the safety and efficacy of Sacituzumab Govitecan and Zimberelimab with stereotactic radiation (SRS) in participants with metastatic triple negative breast cancer with brain metastases, compared to treatment with Sacituzumab Govitecan alone.

Phase:

PHASE1

Details

Lead Sponsor:

H. Lee Moffitt Cancer Center and Research Institute

Collaborator:

Gilead Sciences

Treatments:

Radiosurgery
sacituzumab govitecan
zimberelimab